Pricing Log in Create free account
Friday 6 November 2026 Export KRYS’s income statement to Excel — free account

Krystal Biotech, Inc.

KRYS Healthcare Biotechnology

Krystal Biotech, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $389.1 million, up 33.9% from fiscal 2024.

Revenue
+30.2%
EPS
−22.3%
Free cash flow
+137.8%

Quarter to September 2026, against a year earlier

300.31 0.06 +0.02%
Market cap
$8.9B
P/E
39.2×
Fwd P/E
45.7×
Dividend yield
—
F-score
7/9
Altman Z
39.03
Beneish M
−2.27
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Valuation Filings

Krystal Biotech, Inc. 10-Q filed Aug 3, 2026

Fiscal Q2 2026 · Period ended Jun 30, 2026 · Filed · accepted 7:03 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed May 4, 2026: no comparison — incorporated by reference